Kirkland & Ellis represents Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), which announced today its agreement with Takeda Pharmaceutical Company Limited (TOKYO:4502) to establish an unprecedented partnership in Japan. The strategic move between Takeda, an R&D driven pharmaceutical company which has a long history as a leading company in Japan, and Teva, among the top ten pharmaceutical companies in the world and the global leader in generics, will form a new business venture to meet the wide-ranging needs of patients and growing importance of generics in Japan. Teva will have a 51 percent stake in the new company and Takeda will have 49 percent. Subject to standard regulatory approvals, the business venture is expected to start operating in the second calendar quarter of 2016, and will offer patients and the healthcare system the portfolio of Teva’s high-quality generic medicines and Takeda’s long listed products. Further details of the agreement have not been disclosed. More information on the transaction is available here.
The Kirkland team was led by corporate partners Daniel Wolf and Elazar Guttman and associate Jayk Kooper, and intellectual property transactional partner David MacDonald.